Fintel reports that on April 28, 2025, HSBC downgraded their outlook for Eli Lilly and (NYSE:LLY) from Buy to Reduce. Analyst ...

Companies are announcing significant investments in U.S. manufacturing in response to looming tariffs. An AstraZeneca ...

The NBA Hall of Famer joined forces with the telehealth platform to restart his weight loss journey and raise awareness about ...

Wegovy and Zepbound, the two leading weight-loss drugs, together sold less than $5 billion in 2023, according to ...

Dow Jones, S&P500, and Nasdaq 100 post gains as traders await GDP data, inflation reports, and key earnings from Apple, ...

Instead, McDowell snagged an invite, through his friend Donald Trump Jr., to a falconry trip Kennedy hosted. On a sunny day ...

Drugs that bind to and activate the receptors for the hormones GLP-1 and GIP are effective in the treatment of obesity and diabetes. Surprisingly, active substances are currently being developed that ...

Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...

ProQR Therapeutics N.V.’s PRQR share price has dipped by 5.52%, which has investors questioning if this is right time to buy.

Eli Lilly reports 1Q earnings on Thursday, with EPS of $3.05 and revenues of $12.67 billion expected. Stock is up 14.35% in ...

Eli Lilly is set to report Q1 earnings on May 1. Analysts predict strong growth, but margin pressures and guidance revisions ...